Developers gain root access on Google Glass, not yet sure what to do with it

Access to Google's Glass headsets is still limited to a lucky few, but that's more than enough to include several curious coders. Some have had success identifying the hardware contained within, but others are focusing on the software. Cydia founder Jay Freeman posted the above image on Twitter this afternoon to show that he had gained root access on his unit, telling Forbes he relied upon a well-known Android 4.0.4 exploit to take control of its OS. The bad news? He hasn't been able to use it much yet, since the Explorer edition isn't quite ready for prescription glasses wearers. For now, the question of whether the same technique will work on eventual retail versions remains unanswered, as well as what it's actually going to be useful for. Steven Troughton-Smith suggests developers can use it to try out more complicated apps than Google currently allows, including always-on heads-up displays or camera apps. Overcoming any remote deactivation Google may try to enforce or loading your own unauthorized apps are also definite possibilities, though we're sure others will surface soon.

Filed under: Wearables, Google

Comments

Source: Jay Freeman (Twitter), Forbes, 9to5Google

Source: http://www.engadget.com/2013/04/26/google-glass-rooted/?utm_medium=feed&utm_source=Feed_Classic&utm_campaign=Engadget

solar flare joseph kony 2012 arian foster dennis kucinich apple ipad kony kony 2012

Women Turn to Fertility Yoga

Apr 26, 2013 7:00am

Yoga has long been praised for helping people improve their flexibility and core strength. But one Florida yoga instructor believes that the popular practice can also be used to help women conceive.

Sherry Longbottom, a registered nurse and yoga instructor, has developed fertility yoga.? In her classes she is careful to avoid yoga poses that could strain the body; instead, she favors simple gentle poses that help lessen anxiety.

?Our goal is to get blood flow in the pelvic area,? said Longbottom. ?I?m very excited to be helping these women, it?s so rewarding?

While practicing fertility yoga is not exactly as beneficial as in vitro fertilization (IVF) treatments or hormone therapy, Longbottom said yoga can help women trying to conceive by helping them take a moment to relax and calm down.

?We live in fight or flight mode,? said Longbottom. ?That kind of life goes completely against what we?re trying to look for in creating a fertile environment.?

Many of the women attending Longbottom?s class started after they were recommended by the Reproductive Medicine Group in Tampa, Fla., to help them cope. ?She estimates about half of the attendees are receiving some kind of fertility treatment.

?[Yoga] still can?t correct a tubal issue or necessarily correct an egg issue,? Dr. Betsy McCormick of the Reproductive Medicine Group told ABCNews.com affiliate WFTS-TV. ?But what they can do is help someone get through that process.?

Dr. James Goldfarb, the director of infertility and in-vitro fertilization at University Hospital Cleveland, said he approves of patients trying safe alternative therapies such as yoga or acupuncture as long as the patient feels better after a session.

?The bottom line I always tell patients is, it certainly can?t hurt,? said Goldfarb. ?We?re very encouraging [that they] try whatever they find relief through.?

While fertility treatments such as IVF have helped millions of women conceive, Goldfarb said these women often have a tremendous amount of anxiety at the same time.

?To say someone is going through IVF is going to be stressed is like saying someone is going to hit their thumb with their hammer and it?s going to hurt,? said Goldfarb. ?It?s incredibly stressful.?

Longbottom said that the ability of yoga to help with a person?s mental health in addition to their physical health was one reason she wanted to start the fertility yoga class.

?Mind, body and spirit are all tied together; once you address those areas, you?re taking care of your whole body,? said Longbottom.

Source: http://abcnews.go.com/blogs/health/2013/04/26/for-women-trying-to-conceive-fertility-yoga/

thursday night football Butch Jones Star Trek Into Darkness Heisman watch John McAfee Jenny Rivera Pacquiao vs Marquez 4

Gene variations predict chemotherapy side effects

Apr. 9, 2013 ? Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy, a condition that is hard to predict and often debilitating enough to cause cancer patients to stop their treatment early.

Results of the research were presented today at the American Association for Cancer Research Annual Meeting 2013 in Washington, D.C.

The study, which implicates the genes EPHA5, ARHGEF10, and PRX, is the first to mine large swaths of the human genome for predictors of chemotherapy side effects. Further research into these genes and others may enable clinicians to use genomic information to more safely deliver these potentially toxic treatments.

"Our study creates a path for how to approach the whole genome in order to tailor cancer treatments," says Andreas Beutler, M.D., an oncologist at Mayo Clinic Cancer Center and senior author of the study. "That is important because we would not only like to cure people's cancer or help them live longer, but we also wish to provide them with the best quality of life."

Chemotherapy-induced peripheral neuropathy affects an estimated 20 to 30 percent of cancer patients treated with chemotherapy agents. The symptoms can be as mild as a light tingling or numbness, but can progress to a loss of feeling in the hands and feet, or to the point where patients can no longer walk normally and are left with a permanent feeling of numbness or pain. Currently, there is no way to predict which patients undergoing chemotherapy will develop this side effect or to what degree.

There are approximately 50 genes linked to a hereditary form of peripheral neuropathy. However, many of the people who have a mutation in one of these genes experience no symptoms until they are exposed to chemotherapy. Dr. Beutler decided to first consider those 50 genes as the most likely suspects, and then expand his search to the wider human genome for other predictors of chemotherapy-induced peripheral neuropathy.

Dr. Beutler's approach relied on exome sequencing, a type of DNA sequencing that focuses on the exonic regions of the genome that code for functional proteins. These protein-coding regions are believed to harbor about 85 percent of all disease-causing mutations.

Dr. Beutler and his colleagues performed exome sequencing on 20,794 genes from 119 cancer patients, over half of whom had developed chemotherapy-induced peripheral neuropathy during the course of a chemotherapy clinical trial.

First, they looked at the 50 hereditary neuropathy genes and found one -- EPHA5 -- that appeared to predispose the patients to chemotherapy-induced peripheral neuropathy. Next, researchers analyzed the remaining 20,000 genes and discovered two new genes -- ARHGEF10 and PRX -- that are also associated with chemotherapy-induced peripheral neuropathy. They validated those findings in another group of 75 cancer patients.

The results suggest that the two conditions, hereditary neuropathy and chemotherapy-induced peripheral neuropathy, may share genetic roots in some patients. They also point to ways that clinicians can improve cancer treatment. For instance, if clinicians know which patients are at risk for a particular chemotherapy side effect, they can use the information to individualize treatment.

Dr. Beutler and his team plan to expand their study to look at the entire genome, not just the protein-coding regions, in as many as 1,000 cancer patients. Dr. Beutler says any additional genes they find will add to the larger picture of symptom control in cancer treatment.

"What we are doing at Mayo is much larger than just uncovering a handful of genes," says Dr. Beutler. "We are using cutting-edge genomics research to enhance our strengths in clinical trials and develop new methods to individualize medicine."

Co-authors include, Amit Kulkarni, M.B.B.S.; Rahul Kanwar; Rui Qin, Ph.D.; Zhifu Sun, M.D.; Anh Le-Lindqwister, Terry Therneau, Ph.D.; and Charles Loprinzi, M.D., all of Mayo Clinic.

Funding for the study was provided by the American Cancer Society, the National Institutes of Health grants CA124477 and CA37404, the Mayo Clinic Center for Individualized Medicine and the Richard M. Schulze Family Foundation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by Mayo Clinic.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/most_popular/~3/2fR2tyYtLVU/130409110001.htm

ufc on fox 2 supercross christina aguilera etta james funeral sundance film festival the flintstones etta james ufc on fox

Excess estrogen in pregnancy can silence BRCA1 in daughters, increasing breast cancer risk

Apr. 9, 2013 ? Excess estrogen levels during pregnancy can disable, in their daughters, a powerful breast cancer tumor suppressor gene, say researchers at Georgetown Lombardi Comprehensive Cancer Center. They found the DNA repair gene BRCA1 to be silenced in one year-old girls exposed to a high hormonal fetal environment.

The researchers say their study, presented at the AACR Annual Meeting 2013, suggests that BRCA1 silencing by methylation in utero may be an important mechanism that increases breast cancer risk later in life. And they say that, if confirmed, there could be ways of lowering that risk before breast cancer develops.

"We may be able to identify women at increased risk of developing breast cancer by looking for BRCA1 that has been methylated as a marker of having been exposed to excess estrogen levels in utero," says the study's lead author, Leena Hilakivi-Clarke, PhD, a professor of oncology at Georgetown Lombardi.

Not only was BRCA1 silenced by methylation in the one-year-old girls who developed in a highly estrogenic fetal environment, there were other molecular abnormalities that can contribute to breast cancer risk and risk of breast cancer recurrence, says Hilakivi-Clarke.

For the study, the researchers compared the gene DNA methylation profiles of the daughters to publicly available databases collected from a large number of breast cancer patients in the Cancer Genome Atlas (TCGA). They found that those genes with altered methylation in the daughters of women with the highest pregnancy estradiol levels are also differentially methylated in breast cancer patients.

In addition to BRCA1, another gene abnormality found was in the unfolded protein response (UPR) pathway, which has been linked to breast cancer risk and resistance to tamoxifen, a treatment for breast cancer.

Researchers at Virginia Tech, who collaborated with Hilakivi-Clarke on this study, found that the UPR pathway was "hypomethylated" (genes were turned on or highly active), in the one-year old daughters. They further confirmed that the same UPR genes also were hypomethylated in breast cancers in women, compared to normal breast tissue, as well as in breast cancer cells that are resistant to tamoxifen treatment, compared to tamoxifen sensitive breast cancer cells.

"When these UPR genes are activated it means that damaged cells that should die do not, increasing the risk that cancer develops, and that cancer cells do not respond to treatment," says study collaborator, Robert Clarke, DSc, dean for research at Georgetown University Medical Center.

"Given these findings, perhaps we can identify those breast cancer patients who develop resistance to hormonal therapy and are at high risk of recurrence," Hilakivi-Clarke says. "Because several drugs are now available to reverse an increase in gene methylation, it may be possible to reverse the increase in breast cancer risk and prevent development of resistance to tamoxifen in these women."

"It does not matter how BRCA1 is eliminated -- by mutation or epigenetic silencing -- the end result is the same: there is less BRCA1 to defend the cells from becoming cancerous," she says.

In addition to Hilakivi-Clarke and Clarke, authors include Riitta Luoto of the UKK Institute in Tampere, Finland; Xiao Zhang and Jason Xuan of Virginia Tech; and Nguyen Nguyen, Xiyuan Zhang, Jin Lu, and Alan Zwart of Georgetown Lombardi.

U.S. funding for this research was provided by the National Cancer Institute (U54 1U54CA149147 and 1R01CA164384). Funding was also provided by Pirkanmaa Hospital, Academy of Finland, and Ministry of Education and Culture of Finland. Hilakivi-Clarke reports having no personal financial interests related to the study.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by Georgetown University Medical Center, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/health_medicine/genes/~3/ukaeLQrUjM4/130409144839.htm

the last waltz earth day activities mel gibson splunk dark shadows iau msft

Hefty price paid for DNA letter at auction

A bidder paid over $6 million at an auction today (April 10) for a letter British scientist Francis Crick wrote to his 12-year-old son explaining the double-helix structure of the DNA molecule, which he and James Watson had just discovered.

The winning bid was $5.3 million, with the final price tag for the "Secret of Life" letter coming in at $6,059,750, according to Christie's, which handled the sale.

The seven-page handwritten note, dated March 19, 1953, contains diagrams that outline the scientists' model for how "des-oxy-ribose-nucleic-acid (read it carefully)" replicates and encodes instructions for the development and function of living things.

"In other words we think we have found the basic copying mechanism by which life comes from life," Crick wrote to his son, Michael, who was at boarding school at the time, signing off, "lots of love, Daddy." [See Images of Crick's 'Secret of Life' Letter]

As legend has it, when Watson and Crick made their discovery on Feb. 28, 1953, Crick announced inside a local Cambridge pub called the Eagle, "We have discovered the secret of life." Their findings wouldn't be published in the journal Nature until two months later, and the note to Michael is likely one of the first written explanations of the discovery.

"As far as we know this is the first public description of these ideas that have become the keystone of molecular biology and which have spawned a whole new industry and generations of follow on discovery," Michael Crick wrote in Christie's catalogue.

The auction was handled by Christie's, which had valued the letter at $1-2 million dollars, comparing it to a letter Albert Einstein wrote to President Franklin D. Roosevelt warning about the potential of nuclear weapons. Christie's sold that letter in 2002 for just over $2 million.?

According to Christie's, Crick's family plans to give half of the proceeds from the sale of the DNA letter to the Salk Institute in California, where the scientist, who died in 2004, studied consciousness later in his career.

One of Crick's notebooks, (valued between $4,000 and $6,000) snagged a $17,000 bid. And a drawing of Crick made by his wife, Odile Crick, an artist who drew the double helix for her husband and Watson, was auctioned off for $14,000 today. (Christie's had estimated it would sell for $8,000-$12,000).

Those three items were among the Crick-related mementos on sale this week in New York. Tomorrow (April 11), Heritage Auctions will sell the Nobel medal, struck in 23-carat gold, that Crick received for the discovery in 1962, alongside Watson and Maurice Wilkins.

Heritage Auctions has valued the medal and accompanying diploma at $500,000. As of Wednesday afternoon, the standing bid on the items was $280,000. Thursday's sale will also include Crick's award check with his endorsement on the back, the scientist's lab coat, his gardening logs, nautical journals and books.

Follow Megan Gannon on Twitter and Google+. Follow us @livescience, Facebook & Google+. Original article on LiveScience.com.

Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Source: http://news.yahoo.com/whoa-bidder-pays-6-million-crick-dna-letter-184006587.html

in plain sight hunger games movie review bats hunger games review jeff saturday jason smith jon corzine

American Eagle pilot charged with attempting to fly while intoxicated

MINNEAPOLIS (Reuters) - A pilot has been charged with being under the influence of alcohol while getting ready to fly an American Eagle plane from Minneapolis to New York City in January, a spokesman for the Minneapolis-St. Paul International Airport said on Tuesday.

Kolbjorn Kristiansen had been doing pre-flight checks ahead of a morning flight to New York when airport police took him into custody and administered a breath test, which he failed.

Witnesses said they had smelled alcohol when they passed Kristiansen in an airport terminal. His arrest happened before passengers boarded the flight on American Eagle, a regional carrier for AMR Corp's American Airlines.

Kristiansen was charged with three gross misdemeanors in state court after blood tests showed he had a blood-alcohol concentration of 0.09 percent, more than twice the legal limit for a pilot in the state, airport spokesman Patrick Hogan said.

He was charged with operating or attempting to operate an aircraft under the influence of alcohol, operating or attempting to operate an aircraft with alcohol content of 0.04 or more and operating or attempting to operate an aircraft with alcohol content at 0.04 or more within two hours of a flight, he said.

The threshold for pilots in Minnesota is 0.04, as it is under Federal Aviation Administration rules, or about half what it would be for drivers of automobiles. The initial breath test had returned a 0.107 concentration.

Kristiansen, who is from Raleigh, North Carolina, was released on his own recognizance in January and is not flying.

His attorney, Peter Wold, said Tuesday he had seen a copy of the complaint and questioned the charges.

"He did nothing to attempt to fly other than being near that aircraft," Wold said in a telephone interview. "He didn't operate any controls. He didn't accept any directions. He didn't contact the control tower. I don't understand how they think he attempted to fly an aircraft."

(Reporting by David Bailey; Editing by Lisa Shumaker)

Source: http://news.yahoo.com/american-eagle-pilot-charged-attempting-fly-while-intoxicated-031247707--finance.html

king of kings ostara masters 2012 andy kaufman tom watson kawasaki disease resurrection

Virgin Mobile offers $100 rebate to T-Mobile turncoats, now through May 31st

In the wake of T-Mobile's recently unveiled Simple Choice plans, Virgin Mobile is capitalizing on the shakeup by playing a value card of its own. Now through May 31st, the Sprint-owned MVNO is offering $100 credit to all T-Mobile subscribers willing to port their number to Virgin Mobile. Study the numbers for yourself and the deal seems a no-brainer, as Virgin matches T-Mobile's unlimited scheme with a monthly bill of only $55, which rings in $5 less than the UnCarrier's $60 (2.5GB) alternative. Naturally, that's where Virgin Mobile hopes the conversation ends, but we don't need to tell you that there's quite a difference in speed between Virgin's EV-DO / WiMAX service and the speedier HSPA+ / LTE alternative from T-Mobile. That said, if your inner cheapskate is tingling, you'll now find an extra $100 incentive to make the switch.

Filed under: Cellphones, Wireless, Mobile

Comments

Via: Electronista

Source: Virgin Mobile

Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/njalnMy0Fsg/

Diwali elmo Kevin Clash Walmart Black Friday 2012 Paula Broadwell Tilted Kilt Barbara Palvin